News: February 22nd 2012, Eliapharma Services is celebrating its 5th successful year with the introduction for new services "Diagnostic services" in addition to the existing services "bioanalytical services, preclinical services and Quality Control services".
August 24th 2011, Eliapharma Services is proud to announce that it has successfully completed its initial inspection from Health Canada and has obtained its establishment licence to conduct GLP/GMP testing on finished pharmaceutical products.
December 17th 2010, Eliapharma Services Inc. obtained its permit to import Human pathogen(s) from thePublic Health Agency,
December first 2010, Eliapharma Services Inc. offers Quality Control Services for Natural Health Products and Pharmaceutical Products
November 29th 2010, Eliapharma Services Inc. is pleased to announce the acquisition of new ELN which is integrates CS Notebook
October 23-27 2011, American Association of Pharmaceutical Scientists AAPS, Eliapharma Services Boot # 2843, Washington DC
November 8th and until 19th of November 2010, discount on PK and bioanalytical services
September 2, 5-7 2010 at Eliapharma at Bistro l'Aromate , Centropolis (Laval), Networking activity
Tue, 17 Jul 2018 03:12:22 -0400 New AASM guideline recommends use of actigraphy for sleep disorders Actigraphy can be a useful clinical tool for the evaluation of adult and pediatric patients with suspected sleep disorders, including circadian rhythm sleep-wake disorders, according to a clinical practice guideline from the American Academy of Sleep Medicine
Tue, 17 Jul 2018 03:08:06 -0400 Researchers lament the unmet promise of a miracle drug for Alzheimer disease In an editorial entitled "The Unmet Promise of a Miracle Drug for Alzheimer's Disease: Implications for Practice, Policy, and Research," Malaz Boustani, MD, MPH, a Regenstrief Institute research scientist and the founding director of the Indiana University Center for Health Innovation and Implementation Science, and co-authors Philip D. Sloane, MD, MPH and Sheryl Zimmerman, PhD, of the University of North Carolina at Chapel Hill, lament the unmet promise of a miracle drug for Alzheimer disease but are heartened by what they see as encouraging improvements in care for a growing population of older adults, many with dementia.